Literature

Curbside Consults Podcast


By Clement Lee, MD, MSc

Published September 9, 2022

In this episode of Curbside Consults, we examine the latest standards of medical care published by the American Diabetes Association (ADA). We are joined by Dr. Bob Gabbay, who is Chief Science and Medical Officer at the American Diabetes Association, an Associate Professor of Medicine at Harvard Medical School, and one of the authors of the ADA’s new 2022 Standards of Medical Care in Diabetes document.

00:05 – Intro
00:40 – ADA guideline process
02:55 – Framework for new updates
Theme 1: Screening and Diagnosis
03:51 – New recommendations for universal diabetes screening
04:59 – Checkpoint inhibitor-induced diabetes
06:00 – Testing for maturity-onset diabetes of the young (MODY)
07:30 – Screening for diabetes prior to pregnancy
Theme 2: Individualized Care
08:29 – Sodium-glucose cotransporter-2 (SGLT2) inhibitors
09:51 – Finerenone
Theme 3: Comorbidities
10:52 – Diabetes, COVID, and COVID vaccination
11:56 – Nonalcoholic fatty liver disease (NAFLD) and cognitive impairment
13:35 – Diabetes and obesity
Theme 4: Technologies
15:45 – New technologies in diabetes
16:22 – Technologies in the inpatient setting
18:45 – The future of diabetes technology
21:30 – Concluding remarks

Articles discussed in this episode:

1. Draznin B et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022.
2. Perkovic V et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019.
3. Wiviott SD et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019.
4. Pitt B et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med 2021.
5. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022.
6. ADA Standards of Care App

The Curbside Consults series complements the foundational information in Rotation Prep by taking a deep dive into key clinical topics with expert clinicians and educators. These podcasts explore and critique the evidence behind clinical practice and break down statistical concepts for the busy clinical trainee.

res360
Bob Gabbay, MD, PhD, FACP, is Chief Scientific and Medical Officer for the American Diabetes Association (ADA), an Associate Professor of Medicine at Harvard Medical School, and one of the authors of the ADA’s new 2022 Standards of Medical Care in Diabetes document.
res360
Clement Lee, MD, MSc, is a 2021–2022 NEJM Editorial Fellow. He is currently an internal medicine hospitalist at Beth Israel Deaconess Medical Center and a pediatric hospitalist at Lowell General Hospital. He completed his internal medicine-pediatrics residency at Penn-CHOP.
NEJM Knowledge+